carDIo-ttranSSfOrm nucLEar Imaging Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

4 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-19

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will evaluate the change in myocardial uptake of 99m-technetium pyrophosphate (Tc-99m PYP) tracer on serial planar and SPECT imaging in patients enrolled in the CARDIO-TTRansform clinical trial (NCT04136171).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radioisotope Scintigraphy to Establish Incidence of Cardiac Amyloidosis Among Patients With Otherwise Unexplained Cardiac Disease

NCT03098901

Cardiac TTR Amyloidosis

UNKNOWN NA

Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT

NCT04105634

Cardiac Amyloidosis

TERMINATED EARLY_PHASE1

Low Dose One-Day Tc99m Protocol With a High-Efficiency Cardiac Dedicated Gamma Camera For Detection of Coronary Disease

NCT01135095

Chest Pain

COMPLETED NA

Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)

NCT05064839

Transthyretin Cardiac Amyloidosis

COMPLETED PHASE3

A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)

NCT01334918

Coronary Artery Disease (CAD)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter trial of 80 subjects enrolled in the CARDIO-TTRansform randomized clinical trial (NCT04136171) who will undergo baseline and follow up Tc-99m PYP to assess for the change in myocardial uptake of the tracer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyloidosis Transthyretin Amyloid Cardiomyopathy

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with transthyretin amyloid cardiomyopathy enrolled in CARDIO-TTRansform

Patients will undergo serial Tc-99m PYP imaging at baseline, week 61 and end of trial

99m-technetium pyrophosphate scintigraphy

Intervention Type DIAGNOSTIC_TEST

Imaging test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

99m-technetium pyrophosphate scintigraphy

Imaging test

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tc-99m PYP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who were screened and eligible to be enrolled or have been already enrolled in the CARDIO-TTRansform randomized clinical trial (NCT04136171) and have a baseline 99m-technetium pyrophosphate planar and SPECT imaging done within 12 months prior to screening for CARDIO-TTRansform.